
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Screen for iron deficiency regularly, know the hematologic and biochemical markers, and provide appropriate dietary counseling and treatment.






